This one can explode 100-3000%+ even without the cancer asset. We have a whole pipeline (Brilacidin platform) of anti-infective and anti-inflammatory indications that are farther along and a more sure bet than then cancer drug, Kevetrin.

Kevetrin has yet to truly prove itself but, if it does, may be the most versatile and widely used oncology drug of all time.

I think everyone should have at least a little IPIX in the high-risk portion of their portfolio. The risk-reward is just so skewed to favor the upside at this time.